Evidence map›Paper›PMID 32379970›Full record

ArticleJournal of chemical information and modeling2020

Loop Grafting between Similar Local Environments for Fc-Silent Antibodies.

Samo Lešnik, Milan Hodošček, Barbara Podobnik, Janez Konc

Open access · hybridAbstract read
In one paragraph

Article in Journal of chemical information and modeling, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Samo LešnikNational Institute of Chemistry, Hajdrihova 19, SI-1000 Ljubljana, Slovenia.
Milan HodoščekNational Institute of Chemistry, Hajdrihova 19, SI-1000 Ljubljana, Slovenia.ORCID 0000-0002-6728-9318
Barbara PodobnikBiologics Technical Development Mengeš, Technical Research & Development Novartis, Lek Pharmaceuticals d.d., Kolodvorska 27, SI-1234 Mengeš, Slovenia.
Janez KoncNational Institute of Chemistry, Hajdrihova 19, SI-1000 Ljubljana, Slovenia.ORCID 0000-0003-0160-3375
National Institute of Chemistry · SI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reduction of the affinity of the fragment crystallizable (Fc) region with immune receptors by substitution of one or a few amino acids, known as Fc-silencing, is an established approach to reduce the immune effector functions of monoclonal antibody therapeutics. This approach to Fc-silencing, however, is problematic as it can lead to instability and immunogenicity of the developed antibodies. We evaluated loop grafting as a novel approach to Fc-silencing in which the Fc loops responsible for immune receptor binding were replaced by loops of up to 20 amino acids from similar local environments in other human and mouse antibodies. Molecular dynamics simulations of the designed variants of an Fc region in a complex with the immune receptor FcγIIIa confirmed that loop grafting potentially leads to a significant reduction in the binding of the antibody variants to the receptor, while retaining their stability. In comparison, standard variants with less than eight substituted amino acids showed possible instability and a lower degree of Fc-silencing due to the occurrence of compensatory interactions. The presented approach to Fc-silencing is general and could be used to modulate undesirable side effects of other antibody therapeutics without affecting their stability or increasing their immunogenicity.

Indexed as

Immunoglobulin GReceptors, IgGAnimalsAntibodies, MonoclonalMiceProtein BindingAntibodies, MonoclonalImmunoglobulin GReceptors, IgG

Identifiers

PMID32379970
PMCPMC7686954
OpenAlexW3021730396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.